A F A D Schauwvlieghe1, A G Vonk2, E P Buddingh3, R A S Hoek4, V A Dalm5, C H W Klaassen2, B J A Rijnders1. 1. Department of Internal Medicine, Section of Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands. 2. Department of Medical Microbiology, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Department of Pediatrics, Division of Infectious Diseases and Immunology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, The Netherlands. 4. Department of Pulmonary Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands. 5. Department of Internal Medicine, Division of Clinical Immunology and Department of Immunology, Erasmus MC, Rotterdam, The Netherlands.
Abstract
BACKGROUND: The AsperGenius® assay is a multiplex real-time PCR test that allows the simultaneous detection of Aspergillus species and identification of the most common mutations in the Aspergillus fumigatus cyp51A gene conferring resistance (TR34/L98H and TR46/T289A/Y121F) by using melting curve analysis. Mixed infections with azole-resistant and susceptible A. fumigatus have rarely been described. METHODS: The AsperGenius® multiplex real-time PCR assay (PathoNostics, Maastricht, the Netherlands) was used on bronchoalveolar lavage (BAL) samples of 91 consecutive patients with a suspected invasive Aspergillus infection at the Erasmus MC University Medical Center, Rotterdam. RESULTS: In three cases the AsperGenius® assay indicated the simultaneous presence of WT and mutant genes (two patients with TR34/L98H mutation and one patient with TR46/T289A/Y121F mutation) and therefore mixed infections with azole-susceptible and -resistant isolates. In one of the three cases, the mixed infection was confirmed by phenotypic antifungal testing of multiple A. fumigatus colonies. CONCLUSIONS: The use of a dedicated A. fumigatus cyp51A resistance PCR allowed the detection of mixed infections with azole-resistant and -susceptible Aspergillus strains. These mixed infections may remain undiagnosed with conventional phenotypic susceptibility testing.
BACKGROUND: The AsperGenius® assay is a multiplex real-time PCR test that allows the simultaneous detection of Aspergillus species and identification of the most common mutations in the Aspergillus fumigatus cyp51A gene conferring resistance (TR34/L98H and TR46/T289A/Y121F) by using melting curve analysis. Mixed infections with azole-resistant and susceptible A. fumigatus have rarely been described. METHODS: The AsperGenius® multiplex real-time PCR assay (PathoNostics, Maastricht, the Netherlands) was used on bronchoalveolar lavage (BAL) samples of 91 consecutive patients with a suspected invasive Aspergillus infection at the Erasmus MC University Medical Center, Rotterdam. RESULTS: In three cases the AsperGenius® assay indicated the simultaneous presence of WT and mutant genes (two patients with TR34/L98H mutation and one patient with TR46/T289A/Y121F mutation) and therefore mixed infections with azole-susceptible and -resistant isolates. In one of the three cases, the mixed infection was confirmed by phenotypic antifungal testing of multiple A. fumigatus colonies. CONCLUSIONS: The use of a dedicated A. fumigatus cyp51A resistance PCR allowed the detection of mixed infections with azole-resistant and -susceptible Aspergillus strains. These mixed infections may remain undiagnosed with conventional phenotypic susceptibility testing.
Authors: A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl Journal: Stud Mycol Date: 2021-05-10 Impact factor: 16.097
Authors: J Peter Donnelly; Sharon C Chen; Carol A Kauffman; William J Steinbach; John W Baddley; Paul E Verweij; Cornelius J Clancy; John R Wingard; Shawn R Lockhart; Andreas H Groll; Tania C Sorrell; Matteo Bassetti; Hamdi Akan; Barbara D Alexander; David Andes; Elie Azoulay; Ralf Bialek; Robert W Bradsher; Stephane Bretagne; Thierry Calandra; Angela M Caliendo; Elio Castagnola; Mario Cruciani; Manuel Cuenca-Estrella; Catherine F Decker; Sujal R Desai; Brian Fisher; Thomas Harrison; Claus Peter Heussel; Henrik E Jensen; Christopher C Kibbler; Dimitrios P Kontoyiannis; Bart-Jan Kullberg; Katrien Lagrou; Frédéric Lamoth; Thomas Lehrnbecher; Jurgen Loeffler; Olivier Lortholary; Johan Maertens; Oscar Marchetti; Kieren A Marr; Henry Masur; Jacques F Meis; C Orla Morrisey; Marcio Nucci; Luis Ostrosky-Zeichner; Livio Pagano; Thomas F Patterson; John R Perfect; Zdenek Racil; Emmanuel Roilides; Marcus Ruhnke; Cornelia Schaefer Prokop; Shmuel Shoham; Monica A Slavin; David A Stevens; George R Thompson; Jose A Vazquez; Claudio Viscoli; Thomas J Walsh; Adilia Warris; L Joseph Wheat; P Lewis White; Theoklis E Zaoutis; Peter G Pappas Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079
Authors: Lilyann Novak-Frazer; Samuel P Anees-Hill; Darin Hassan; Rikesh Masania; Caroline B Moore; Malcolm D Richardson; David W Denning; Riina Rautemaa-Richardson Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790